Anticoagulation Prepared by Cherie Gan.

Slides:



Advertisements
Similar presentations
Evidence-Based Management of Anticoagulant Therapy
Advertisements

AF and the New Oral Anti-Coagulants
Prosthetic Valve; Anticoagulation After ICH Dr.Tahsin.N.
What a Bloody Mess! A/Professor Kent Robinson Senior Staff Specialist, Liverpool & Campbelltown Hospitals.
Warfarin toxicity Presented by: Dr.Somaia Janah Presented by: Dr.Somaia Janah.
Dr. Abdullah Ahmad Ghazi (R5) KSMC 8 May  TURP  gold standard in BPH  Using of A-Cog & A-Plt is increasing.  4% on A-Cog  37% on A-plt.
DURNER L.,BOURDOUMIS A., MASOOD J., BUCHHOLZ N. ROYAL LONDON HOSPITAL, BARTSHEALTH NHS TRUST ROYAL DEVON AND EXETER NHS TRUST HOMERTON UNIVERSITIY HOSPITAL.
Question: How should we manage periprocedural anticoagulation? Paper: Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures Todd.
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
NEW ORAL ANTICOAGULANTS
ANAESTHESIA AND ANTICOAGULANTS
Chapter Eight Venous Disease Coalition Safe Use of Oral Anticoagulants VTE Toolkit.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Dalia Elfawy., MD Lecturer of Anesthesia and ICU Ain Shams University 2014 RAPID REVERSAL OF ANTICOAGULATION IN TRAUMA PATIENTS.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
BLOOD PHARMACOLOGY Peer Support Case 1 Mrs A recently seen one of your colleagues complaining of fatigue. Her blood test results are now back and.
Andres Ferber MD September
ANTICOAGULANT BY :DR ISRAA OMAR.
WARFARIN AN OVERVIEW.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Role of Factor Concentrates in Perioperative Coagulopathies Dr Neville Gibbs Department of Anaesthesia Sir Charles Gairdner Hospital.
 Background  Cost  Benefit  Complication.
VCU Death and Complications Conference
Anticoagulation ACCP guidelines 2012
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Anticoagulants and reversal
General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental.
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Biochemistry of Vitamin K GIT Block Dec Overview Types and chemistry of vitamin K Sources and daily requirements Functions Synthesis of  -carboxyglutamate.
Anticoagulation Update
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Warfarin Therapy Aaqid Akram MBChB (2013) Clinical Education Fellow.
April 23, 2015 Mini-Lecture Nathan King M.D. Anticoagulation Reversal Part 1: Warfarin.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Dr. Hadab A. Mohamed. BACKGROUND Temporary interruption Thrombotic risk Continuation Bleeding risk A great challenge, especially in the emergency setting.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy Dr. Morteza Safi Professor of interventional cardiology Cardiovascular Research.
Low Procedural Bleed Risk
The management of anti-thrombotics in patients undergoing GI endoscopy
Evidence-Based Management of Anticoagulant Therapy
Haemostasis An efficient Mechanism is functional to maintain the circulation as a transport system. It prevents blood loss from damaged vessels. It also.
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
Treatment and Prevention of Heparin-Induced Thrombocytopenia
You can never be too Thin…. An Update on NOACs
Warfarin Toxicity Treatment & Management
Biochemistry of Vitamin K
Anticoagulants in the Treatment of Venous Thromboembolism
Pharmacokinetics: Warfarin
Biochemistry of Vitamin K
Ortho Warfarin Dosing Protocol
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Dr.Avinash Jadhao 10/6/ Vitamin K- Chemistry Vitamin K represents a group of lipophilic and hydrophobic vitamins. Three compounds have the biological.
Oral Anticoagulants in AFa,b A Brief History.
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Selecting NOACs for High-Risk Patients
Reversal of Direct Oral Anticoagulants (DOAC)
Reversal Strategies for VKA: Truths and Misconceptions
Pharmacogenomics Genes and Drugs.
Oral Anticoagulant Reversal Agents
Anticoagulant Reversal
Bridging Anticoagulation
by Alex C. Spyropoulos, and James D. Douketis
Periprocedural Management of Patients on Anticoagulation
Biochemistry of Vitamin K
(p for noninferiority = 0.01)
Management of Antithrombotic Medication in surgical patient
Drug Summary Info Document Request / monitor Goal of therapy Action
Presentation transcript:

Anticoagulation Prepared by Cherie Gan

https://tinyurl.com/y6u2ooyo QUIZ https://tinyurl.com/y6u2ooyo

Let’s talk about warfarin first

warfarin Mechanism Inhibits Vit K epoxide reductase needed to reduce Vit K into the reduced form. Reduced Vit K is needed for the enzyme that synthesises Factors II VII IX X and Protein C and S.

Mechanism of action of warfarin Reduced vitamin K Oxidised vitamin K Warfarin is made in liver and released as inactive precursors. To make them functional need to gamma carboxylate Need vitamin k Gamma carboxylation Inactive precursor FII, VII, IX, X Functional FII, VII, IX, X Glutamic acid carboxy-glutamic acid

Mechanism of action of warfarin Vitamin K reductase Reduced vitamin K Oxidised vitamin K Gamma carboxylation Inactive precursor FII, VII, IX, X Functional FII, VII, IX, X Glutamic acid carboxy-glutamic acid

Warfarin initiation Bridging w Heparin When initiating warfarin, need to overlap with heparin for about five days and until INR is therapeutic (≥2) for at least 24h, before stopping heparin Reason is because Warfarin inhibits Protein C and S also, which have short half-lives, and these are anticoagulant factors. If you do not do heparin bridging, then there is a risk of paradoxical thromboembolism when initiating warfarin Protein C and S have a short half life while FX has a half-life of 5 days Therefore 5 days overlap with heparin is required for FX levels to decrease sufficiently and have a true antithrombotic effect Hence to start LMWH and warfarin together and to overlap for at least 5 days or when INR >2 for at least 24 hours (whichever is the longer)- to be safe we try to fulfill BOTH of these

Interactions with drugs and food To avoid labile INR, need to keep the dietary intake of Vit K relatively constant (same amount of green leafy vegetables every day) Avoid foods that can affect the liver enzymes eg TCM

Drugs that interact with warfarin

What to do w over-warfarinisation Ensure no major bleed in brain Identify sites of bleed Possible ways to reverse the over-warfarinisation Can overcome warfarin effect by giving vitamin K, because there are actually 2 vitamin k reducing enzymes. One less sensitive (vit K reductase) and vit k can bypass Can bypass warfarin effect by giving functional clotting factor (FFP/Prothrombin Complex Concentrate) But rmb that still need to give IV VIt K because the half-lives of the factors are very short

Warfarin reversal In major bleeding or emergency reversal for surgery IV vitamin K 5-10 mg and Factor replacement with Prothrombin Complex Concentrate (PCC) or FFP If minor bleeding – stop warfarin and give low dose vitamin K (2 mg PO or 1 mg IV)

NO BLEED: INR > 5 but not bleeding: 1-2 doses of warfarin withheld and maintenance dose reduced, investigate cause of elevated INR INR ≥ 8.0, asymptomatic :Oral vitamin K 1-5 mg, recheck INR next day Surgery that requires reversal of warfarin, can be delayed 6- 12 hr: IV vitamin K Surgery requiring reversal of warfarin, cannot be delayed: PCC and IV vitamin K

Peri- op management of warfarin Peri- op management of warfarin. Stopping warfarin before elective surgery The most appropriate perioperative strategy is to stop warfarin 5 days before the procedure and forego bridging anticoagulation. This patient is scheduled for an invasive procedure with a high risk of bleeding and therefore requires discontinuation of warfarin for surgery. Stopping warfarin 5 days before surgery usually achieves the standard target of an INR of less than 1.5. HOWEVER, MUST DECIDE IF PT IS AT HIGH RISK OF THROMBOEMBOLISM- IF SO, WILL NEED BRIDGING W HEPARIN OR CLEXANE (no role for NOACs for bridging) In perioperative patients who require interruption of chronic anticoagulation, the need for bridging anticoagulation must be determined, typically with the use of the CHADS2score + indication for anticoagulation in the first place eg Bridging typically done if high risk patient eg prosthetic valve/ high chadsvas score

Adapted from Douketis JD, Spyropoulos AC, Spencer FA, et al Adapted from Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e326S-e350S. PMID: 22315266

When bridging w clexane vs heparin Before operation, heparin can be stopped 6-12h before op Clexane must be stopped 24h before op (longer half life)

Post op restarting of warfarin Heparin / clexane should be given for at least 5 days and only discontinued at that time if the INR is therapeutic ie INR >2 for 24 hours. Warfarin may be initiated on the first or second day of heparin therapy. Because factor II and X levels require at least 5 days to decline sufficiently, parenteral anticoagulation should overlap with warfarin for at least 5 days and until an INR of 2 or more is achieved.

Heparin and LMW Heparin

Unfractionated heparin

LMW heparin eg clexane ie enoxaparin

NOACs

Valvular AF can only use warfarin. NOACs not proven for valvular AF Advanced renal impairment, mechanical valve replacement, valvular AF  can only use warfarin and not NOACs!

Only NOAC w antidote is dabigatran. Antidote is idaricizumab

Rivoroxaban is once daily dosing in AF vs dabigatran and apixaban are BD All cannot be used in renal failure

Credits NUH warfarin protocol NUH Dr Koh LP lecture